| Advance Theraputic Services Inc | |
|
North Lauderdale 7431 Sw 8th Court Northlauderdale FL 33068-3306 | |
| (954) 270-5626 | |
| Not Available |
| Full Name | Advance Theraputic Services Inc |
|---|---|
| Speciality | Counselor - Mental Health |
| Location | North Lauderdale, Northlauderdale, Florida |
| Authorized Official Name and Position | Julia Mitsy Mcdonald (CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 9542705626 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Advance Theraputic Services Inc 5456 Nw 122nd Dr Coral Springs FL 33076-3638 Ph: (954) 270-5626 | Advance Theraputic Services Inc North Lauderdale 7431 Sw 8th Court Northlauderdale FL 33068-3306 Ph: (954) 270-5626 |
| NPI Number | 1134869993 |
|---|---|
| Provider Enumeration Date | 03/30/2022 |
| Last Update Date | 03/30/2022 |
| Certification Date | 03/18/2022 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134869993 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
News Archive
A researcher at New York Institute of Technology College of Osteopathic Medicine (NYITCOM) has secured a grant from the National Institutes of Health (NIH) to study how certain brain cells respond to chronic stress.
B vitamins can mitigate the impact of fine particle pollution on cardiovascular disease, according to new research conducted at Columbia University's Mailman School of Public Health.
Researchers at the Universitat Jaume I in Castellón, Spain, have developed a new light-activated antimicrobial material for use in the fight against the most common hospital infections.
Non-alcoholic fatty liver disease has become a global epidemic. There is not only a great interest worldwide to understand the causes and consequences of fatty liver disease, but also to diagnose fatty liver disease at an early stage.
iBio, Inc. today announced that its proprietary iBioLaunch Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine candidate for human hookworm disease.
› Verified 8 days ago